Gary Flynn, President and Chief Scientific Officer
$500,000 / 3 years Awarded 2017 |
Vibliome TherapeuticsBozeman, MT
About
Vibliome was incorporated in 2017 to establish proof of concept in humans for a new family of highly selective small molecule kinase inhibitors offering both reversible and irreversible binding to a broad range of targets. The company is focusing on validated and promising new kinase targets while co-targeting relevant compensatory pathways to improve patient outcomes. Our Grant
The project will focus on the development of a Vibliome drug candidate that is a highly selective inhibitor of homeodomain-interacting protein kinase 4 (HIPK4). Researchers at Stanford, led by James Chen, Professor and Chair of the Department of Chemical and Systems Biology, have determined that the protein kinase HIPK4 is essential for male fertility. Mice lacking the HIPK4 gene have impaired spermiogenesis but are otherwise healthy, supporting HIPK4 as a therapeutic target for reversible male contraception. |
Publications
He, Qin, Jingxue Shi, Hong Sun, Jie An, Ying Huang, and M. Saeed Sheikh. “Characterization of Human Homeodomain-Interacting Protein Kinase 4 (HIPK4) as a Unique Member of the HIPK Family.” Molecular and Cellular Pharmacology 2, no. 2 (2010): 61–68.
He, Qin, Jingxue Shi, Hong Sun, Jie An, Ying Huang, and M. Saeed Sheikh. “Characterization of Human Homeodomain-Interacting Protein Kinase 4 (HIPK4) as a Unique Member of the HIPK Family.” Molecular and Cellular Pharmacology 2, no. 2 (2010): 61–68.
